3-deacetylvecuronium: RN given refers to parent cpd (2beta,3alpha,5alpha,16beta,17beta)-isomer; structure given in first source [MeSH]
3-Hydroxyvecuronium : no description available [CHeBI]
ID Source | ID |
---|---|
PubMed CID | 11849104 |
CHEBI ID | 187362 |
MeSH ID | M0138188 |
Synonym |
---|
3-hydroxyvecuronium |
74041-85-3 |
CHEBI:187362 |
[(2s,3s,5s,8r,9s,10s,13s,14s,16s,17r)-3-hydroxy-10,13-dimethyl-16-(1-methylpiperidin-1-ium-1-yl)-2-piperidin-1-yl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl] acetate |
3-deacetylvecuronium |
3-desacetylvecuronium |
unii-7gjt8823h1 |
7gjt8823h1 , |
piperidinium, 1-((2beta,3alpha,5alpha,16beta,17beta)-17-(acetyloxy)-3-hydroxy-2-(1-piperidinyl)androstan-16-yl)-1-methyl- |
desacetylvecuronium |
piperidinium, 1-((2.beta.,3.alpha.,5.alpha.,16.beta.,17.beta.)-17-(acetyloxy)-3-hydroxy-2-(1-piperidinyl)androstan-16-yl)-1-methyl- |
3-deacetylvecuronium cation |
1-(17.beta.-(acetyloxy)-3.alpha.-hydroxy-2.beta.-(piperidin-1-yl)-5.alpha.-androstan-16.beta.-yl)-1-methylpiperidinium |
vecuronium bromide impurity c [ep impurity] |
org-7268 cation |
Q27268251 |
Class | Description |
---|---|
steroid ester |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 2 (18.18) | 18.7374 |
1990's | 7 (63.64) | 18.2507 |
2000's | 1 (9.09) | 29.6817 |
2010's | 1 (9.09) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 2 (16.67%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 10 (83.33%) | 84.16% |
Condition | Indicated | Studies | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Acute Liver Injury, Drug-Induced | 0 | 1991 | 1991 | 33.0 | medium | 0 | 0 | 1 | 0 | 0 | 0 | |
Benign Supratentorial Neoplasms | 0 | 2004 | 2004 | 20.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 | |
Chemical and Drug Induced Liver Injury | 0 | 1991 | 1991 | 33.0 | medium | 0 | 0 | 1 | 0 | 0 | 0 | |
ENT Diseases | 0 | 1996 | 1996 | 28.0 | medium | 1 | 0 | 1 | 0 | 0 | 0 | |
Kidney Diseases | 0 | 1991 | 1991 | 33.0 | medium | 0 | 0 | 1 | 0 | 0 | 0 | |
Liver Diseases | 0 | 1991 | 1991 | 33.0 | medium | 0 | 0 | 1 | 0 | 0 | 0 | |
Liver Dysfunction | 0 | 1991 | 1991 | 33.0 | medium | 0 | 0 | 1 | 0 | 0 | 0 | |
Muscle Contraction | 0 | 1992 | 1992 | 32.0 | medium | 0 | 0 | 1 | 0 | 0 | 0 |
Article | Year |
---|---|
The pharmacodynamics and pharmacokinetics of the metabolite 3-desacetylvecuronium (ORG 7268) and its parent compound, vecuronium, in human volunteers. The Journal of pharmacology and experimental therapeutics, , Volume: 270, Issue:3 | 1994 |
Antagonism of vecuronium by one of its metabolites in vitro. European journal of pharmacology, , Nov-03, Volume: 222, Issue:1 | 1992 |
Article | Year |
---|---|
Influence of chronic phenytoin administration on the pharmacokinetics and pharmacodynamics of vecuronium. Anesthesiology, , Volume: 100, Issue:3 | 2004 |
Pharmacokinetics and pharmacokinetic-dynamic relationship between rapacuronium (Org 9487) and its 3-desacetyl metabolite (Org 9488). Anesthesia and analgesia, , Volume: 88, Issue:3 | 1999 |
The pharmacodynamics and pharmacokinetics of the metabolite 3-desacetylvecuronium (ORG 7268) and its parent compound, vecuronium, in human volunteers. The Journal of pharmacology and experimental therapeutics, , Volume: 270, Issue:3 | 1994 |
Pharmacokinetics, neuromuscular effects, and biodisposition of 3-desacetylvecuronium (Org 7268) in cats. Anesthesiology, , Volume: 74, Issue:6 | 1991 |
Pharmacokinetics of steroidal muscle relaxants in isolated perfused rat liver. Biochemical pharmacology, , Oct-06, Volume: 44, Issue:7 | 1992 |
Article | Year |
---|---|
Antagonism of vecuronium by one of its metabolites in vitro. European journal of pharmacology, , Nov-03, Volume: 222, Issue:1 | 1992 |